Dr. Agarwal's Eye [DRAGARWQ] vs Indraprastha Medical [INDRAMEDCO] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Dr. Agarwal's Eye wins in 7 metrics, Indraprastha Medical wins in 13 metrics, with 0 ties. Indraprastha Medical appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricDr. Agarwal's EyeIndraprastha MedicalBetter
P/E Ratio (TTM)40.3524.13Indraprastha Medical
Price-to-Book Ratio11.147.00Indraprastha Medical
Debt-to-Equity Ratio158.945.49Indraprastha Medical
PEG Ratio1.811.61Indraprastha Medical
EV/EBITDA20.3215.36Indraprastha Medical
Profit Margin (TTM)13.96%12.21%Dr. Agarwal's Eye
Operating Margin (TTM)22.71%17.25%Dr. Agarwal's Eye
EBITDA Margin (TTM)22.71%17.25%Dr. Agarwal's Eye
Return on Equity26.07%26.98%Indraprastha Medical
Return on Assets (TTM)8.91%18.90%Indraprastha Medical
Free Cash Flow (TTM)$-83.80M$1.20BIndraprastha Medical
Dividend Yield0.11%0.95%Indraprastha Medical
1-Year Return4.92%9.20%Indraprastha Medical
Price-to-Sales Ratio (TTM)5.643.04Indraprastha Medical
Enterprise Value$26.43B$38.89BIndraprastha Medical
EV/Revenue Ratio6.382.83Indraprastha Medical
Gross Profit Margin (TTM)77.64%38.19%Dr. Agarwal's Eye
Revenue per Share (TTM)$881$150Dr. Agarwal's Eye
Earnings per Share (Diluted)$123.07$18.86Dr. Agarwal's Eye
Beta (Stock Volatility)-0.360.57Dr. Agarwal's Eye
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Dr. Agarwal's Eye vs Indraprastha Medical Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Dr. Agarwal's Eye-0.31%2.98%9.84%14.47%16.54%-23.53%
Indraprastha Medical1.51%3.48%-3.24%-7.50%14.75%-14.65%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Dr. Agarwal's Eye4.92%358.10%1,895.43%3,647.65%6,296.19%14,656.04%
Indraprastha Medical9.20%642.22%819.28%590.66%890.15%874.50%

News Based Sentiment: Dr. Agarwal's Eye vs Indraprastha Medical

Dr. Agarwal's Eye

News based Sentiment: POSITIVE

September was a strong month for Dr. Agarwal's, marked by impressive financial results, a commitment to shareholder returns through a 35% dividend, and increasing institutional investor confidence. Long-term projections from Walletinvestor.com further reinforce a positive investment outlook, suggesting significant potential for future growth.

View Dr. Agarwal's Eye News Sentiment Analysis

Indraprastha Medical

News based Sentiment: MIXED

September presented a mixed bag for Indraprastha Medical, with slightly disappointing Q2 results countered by a consistent dividend and an attractive valuation. While profitability declined, the company maintains a commitment to shareholder returns and appears undervalued compared to its peers, creating a complex investment picture.

View Indraprastha Medical News Sentiment Analysis

Performance & Financial Health Analysis: Dr. Agarwal's Eye vs Indraprastha Medical

MetricDRAGARWQINDRAMEDCO
Market Information
Market Cap i₹23.46B₹42.43B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,476115,470
90 Day Avg. Volume i3,361212,862
Last Close₹4,950.65₹462.40
52 Week Range₹3,500.00 - ₹7,300.00₹307.25 - ₹572.00
% from 52W High-32.18%-19.16%
All-Time High₹7,300.00 (Dec 30, 2024)₹572.00 (Jan 06, 2025)
% from All-Time High-32.18%-19.16%
Growth Metrics
Quarterly Revenue Growth0.17%0.05%
Quarterly Earnings Growth0.22%0.15%
Financial Health
Profit Margin (TTM) i0.14%0.12%
Operating Margin (TTM) i0.23%0.17%
Return on Equity (TTM) i0.26%0.27%
Debt to Equity (MRQ) i158.945.49
Cash & Liquidity
Book Value per Share (MRQ)₹445.96₹65.04
Cash per Share (MRQ)₹52.76₹35.08
Operating Cash Flow (TTM) i₹738.70M₹1.78B
Levered Free Cash Flow (TTM) i₹546.50M₹1.61B
Dividends
Last 12-Month Dividend Yield i0.11%0.95%
Last 12-Month Dividend i₹5.00₹4.50

Valuation & Enterprise Metrics Analysis: Dr. Agarwal's Eye vs Indraprastha Medical

MetricDRAGARWQINDRAMEDCO
Price Ratios
P/E Ratio (TTM) i40.3524.13
Forward P/E i510.88182.00
PEG Ratio i1.811.61
Price to Sales (TTM) i5.643.04
Price to Book (MRQ) i11.147.00
Market Capitalization
Market Capitalization i₹23.46B₹42.43B
Enterprise Value i₹26.43B₹38.89B
Enterprise Value Metrics
Enterprise to Revenue i6.382.83
Enterprise to EBITDA i20.3215.36
Risk & Other Metrics
Beta i-0.360.57
Book Value per Share (MRQ) i₹445.96₹65.04

Financial Statements Comparison: Dr. Agarwal's Eye vs Indraprastha Medical

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)DRAGARWQINDRAMEDCO
Revenue/Sales i₹1.17B₹3.65B
Cost of Goods Sold i₹261.40M₹2.26B
Gross Profit i₹907.80M₹1.39B
Research & Development iN/AN/A
Operating Income (EBIT) i₹265.50M₹629.70M
EBITDA i₹379.30M₹800.50M
Pre-Tax Income i₹231.90M₹683.10M
Income Tax i₹59.30M₹168.50M
Net Income (Profit) i₹172.60M₹514.60M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)DRAGARWQINDRAMEDCO
Cash & Equivalents i₹111.60M₹614.80M
Total Current Assets i₹559.40M₹4.31B
Total Current Liabilities i₹869.80M₹1.79B
Long-Term Debt i₹3.06B₹305.40M
Total Shareholders Equity i₹2.10B₹5.97B
Retained Earnings i₹1.99B₹4.75B
Property, Plant & Equipment i₹1.37B₹2.60B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)DRAGARWQINDRAMEDCO
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricDRAGARWQINDRAMEDCO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i1,476115,470
Average Daily Volume (90 Day) i3,361212,862
Shares Outstanding i4.70M91.67M
Float Shares i1.11M41.01M
% Held by Insiders i0.81%0.58%
% Held by Institutions i0.02%0.03%

Dividend Analysis & Yield Comparison: Dr. Agarwal's Eye vs Indraprastha Medical

MetricDRAGARWQINDRAMEDCO
Last 12-Month Dividend i₹5.00₹4.50
Last 12-Month Dividend Yield i0.11%0.95%
3-Year Avg Annual Dividend i₹4.50₹4.00
3-Year Avg Dividend Yield i0.12%1.26%
3-Year Total Dividends i₹13.50₹12.00
Ex-Dividend DateNov 08, 2024Sep 18, 2025